Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer

被引：25

作者：

Garcia, Christine A. ^{[1
]}

Wu, Shenhong ^{[2
,3
]}

机构：

[1] Univ Pittsburgh, Med Ctr, Dept Med, Div Hematol Oncol, Pittsburgh, PA USA

[2] Stony Brook Univ Hosp, Div Hematol Oncol, Dept Med, Stony Brook, NY USA

[3] Northport VA Med Ctr, Northport, NY USA

来源：

CANCER INVESTIGATION | 2016年 / 34卷 / 10期

关键词：

Infections; mTOR inhibitor; everolimus; temsirolimus; cancer; RENAL-CELL CARCINOMA; TUBEROUS SCLEROSIS COMPLEX; METASTATIC BREAST-CANCER; ADVERSE EVENT MANAGEMENT; PLACEBO-CONTROLLED TRIAL; CONTROLLED PHASE-3 TRIAL; DOUBLE-BLIND; GLIOBLASTOMA-MULTIFORME; NEUROENDOCRINE TUMORS; TARGETED THERAPIES;

D O I：

10.1080/07357907.2016.1242009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The risk of infection attributable to mTOR inhibitors has not been determined. Databases from PubMed and abstracts presented at the American Society of Clinical Oncology meetings were searched. Eligible studies included randomized controlled trials, in which everolimus or temsirolimus was compared with placebo. A total of 12 trials were included. The attributable incidences of all-grade and high-grade infections to mTOR inhibitors were 9.3% (95% confidence interval (CI): 5.8-14.6%) and 2.3% (95% CI: 1.2-4.4%) respectively. The risk varied widely with tumor types (p <.001). There was substantial risk of infection attributable to mTOR inhibitors everolimus and temsirolimus.

引用

页码：521 / 530

页数：10

共 30 条

[1] Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial [J].

Andre, Fabrice ;

O'Regan, Ruth ;

Ozguroglu, Mustafa ;

Toi, Masakazu ;

Xu, Binghe ;

Jerusalem, Guy ;

Masuda, Norikazu ;

Wilks, Sharon ;

Arena, Francis ;

Isaacs, Claudine ;

Yap, Yoon-Sim ;

Papai, Zsuzsanna ;

Lang, Istvan ;

Armstrong, Anne ;

Lerzo, Guillermo ;

White, Michelle ;

Shen, Kunwei ;

Litton, Jennifer ;

Chen, David ;

Zhang, Yufen ;

Ali, Shyanne ;

Taran, Tetiana ;

Gianni, Luca .

LANCET ONCOLOGY, 2014, 15 (06) :580-591

[2]

[Anonymous], 2006, COMMON TERMINOLOGY C

[3] Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma - A phase 2 trial in the North Central Cancer Treatment Group [J].

Ansell, Stephen M. ;

Inwards, David J. ;

Rowland, Kendrith M., Jr. ;

Flynn, Patrick J. ;

Morton, Roscoe F. ;

Moore, Dennis F., Jr. ;

Kaufmann, Scott H. ;

Ghobrial, Irene ;

Kurtin, Paul J. ;

Maurer, Matthew ;

Allmer, Christine ;

Witzig, Thomas E. .

CANCER, 2008, 113 (03) :508-514

[4] Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study [J].

Bachelot, Thomas ;

Bourgier, Celine ;

Cropet, Claire ;

Ray-Coquard, Isabelle ;

Ferrero, Jean-Marc ;

Freyer, Gilles ;

Abadie-Lacourtoisie, Sophie ;

Eymard, Jean-Christophe ;

Debled, Marc ;

Spaeth, Dominique ;

Legouffe, Eric ;

Allouache, Djelila ;

El Kouri, Claude ;

Pujade-Lauraine, Eric .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (22) :2718-2724

[5] Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer [J].

Baselga, Jose ;

Campone, Mario ;

Piccart, Martine ;

Burris, Howard A., III ;

Rugo, Hope S. ;

Sahmoud, Tarek ;

Noguchi, Shinzaburo ;

Gnant, Michael ;

Pritchard, Kathleen I. ;

Lebrun, Fabienne ;

Beck, J. Thaddeus ;

Ito, Yoshinori ;

Yardley, Denise ;

Deleu, Ines ;

Perez, Alejandra ;

Bachelot, Thomas ;

Vittori, Luc ;

Xu, Zhiying ;

Mukhopadhyay, Pabak ;

Lebwohl, David ;

Hortobagyi, Gabriel N. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (06) :520-529

[6] Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial [J].

Bissler, John J. ;

Kingswood, J. Christopher ;

Radzikowska, Elzbieta ;

Zonnenberg, Bernard A. ;

Frost, Michael ;

Belousova, Elena ;

Sauter, Matthias ;

Nonomura, Norio ;

Brakemeier, Susanne ;

de Vries, Petrus J. ;

Whittemore, Vicky H. ;

Chen, David ;

Sahmoud, Tarek ;

Shah, Gaurav ;

Lincy, Jeremie ;

Lebwohl, David ;

Budde, Klemens .

LANCET, 2013, 381 (9869) :817-824

[7]

CARPENTER JT, 2005, P AN M AM SOC CLIN, V23, pA564

[8] Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies [J].

Eisen, Tim ;

Sternberg, Cora N. ;

Robert, Caroline ;

Mulders, Peter ;

Pyle, Lynda ;

Zbinden, Stephan ;

Izzedine, Hassan ;

Escudier, Bernard .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (02) :93-113

[9] Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial [J].

Franz, David Neal ;

Belousova, Elena ;

Sparagana, Steven ;

Bebin, E. Martina ;

Frost, Michael ;

Kuperman, Rachel ;

Witt, Olaf ;

Kohrman, Michael H. ;

Flamini, J. Robert ;

Wu, Joyce Y. ;

Curatolo, Paolo ;

de Vries, Petrus J. ;

Whittemore, Vicky H. ;

Thiele, Elizabeth A. ;

Ford, James P. ;

Shah, Gaurav ;

Cauwel, Helene ;

Lebwohl, David ;

Sahmoud, Tarek ;

Jozwiak, Sergiusz .

LANCET, 2013, 381 (9861) :125-132

[10] Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group study [J].

Galanis, E ;

Buckner, JC ;

Maurer, MJ ;

Kreisberg, JL ;

Ballman, K ;

Boni, J ;

Peralba, JM ;

Jenkins, RB ;

Dakhil, SR ;

Morton, RF ;

Jaeckle, KA ;

Scheithauer, BW ;

Dancey, J ;

Hidalgo, M ;

Walsh, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5294-5304

← 1 2 3 →